HIK.L Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 17:35):

Stats
Dagens volum	468 670
Gjennomsnittsvolum	622 239
Markedsverdi	4.35B
EPS	£0 ( 2024-02-22 )
Last Dividend	£25.00 ( 2023-08-10 )
Next Dividend	£0 ( N/A )
P/E	28.82
ATR14	£1.822 (0.09%)

Volum Korrelasjon

Lang: 0.20 (neutral)

Kort: -0.92 (very strong negative)

Signal:(46.114) Neutral

Hikma Pharmaceuticals PLC Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Hikma Pharmaceuticals PLC Korrelasjon - Valuta/Råvare

-0.22
( neutral )

-0.16
( neutral )

0.15
( neutral )

-0.33
( neutral )

0.44
( neutral )

Hikma Pharmaceuticals PLC Økonomi

Annual	2023
Omsetning:	£2.88B
Bruttogevinst:	£1.39B (48.35 %)
EPS:	£0.860

FY	2023
Omsetning:	£2.88B
Bruttogevinst:	£1.39B (48.35 %)
EPS:	£0.860

FY	2023
Omsetning:	£0
Bruttogevinst:	£0 (0.00 %)
EPS:	£0

FY	2022
Omsetning:	£2.52B
Bruttogevinst:	£1.27B (50.26 %)
EPS:	£0.840

Financial Reports:

No articles found.

Hikma Pharmaceuticals PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£16.00 (N/A)	£0 (N/A)	£29.52 (N/A)	£0 (N/A)	£25.00 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Hikma Pharmaceuticals PLC Dividend Information - Dividend Knight

Dividend Sustainability Score: 9.93 - good (99.32%) | Divividend Growth Potential Score: 3.83 - Decrease likely (23.40%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£0.500	2006-04-26
Last Dividend	£25.00	2023-08-10
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	36	--
Total Paid Out	£347.38	--
Avg. Dividend % Per Year	1.60%	--
Score	4.06	--
Div. Sustainability Score	9.93
Div.Growth Potential Score	3.83
Div. Directional Score	6.88	--

Next Divdend (Est)
(2024-06-25)

£25.96 Estimate 7.54 %

Dividend Stability

0.30 Poor

Dividend Score

4.06

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2006	£0	0.00%
2007	£0	0.00%
2008	£0	0.00%
2009	£0	0.00%
2010	£0	0.00%
2011	£0	0.00%
2012	£0	0.00%
2013	£0	0.00%
2014	£0	0.00%
2015	£0	0.00%
2016	£0	0.00%
2017	£0	0.00%
2018	£25.40	1.92%
2019	£34.00	1.99%
2020	£36.22	1.82%
2021	£37.70	1.47%
2022	£42.00	1.92%
2023	£54.52	3.36%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TRI.L	Dividend Junior	2023-09-28	Annually	31	0.71%
MATE.L	Dividend Knight	2023-06-29	Quarterly	7	2.31%
CRH.L	Dividend Knight	2023-10-19	Semi-Annually	31	2.09%
S32.L	Dividend Junior	2023-09-14	Semi-Annually	9	1.97%
HLMA.L	Dividend Knight	2023-07-13	Semi-Annually	32	0.43%
BAKK.L	Dividend Knight	2023-09-14	Annually	7	4.28%
W7L.L	Dividend Knight	2023-11-09	Annually	8	2.69%
MTVW.L	Dividend Knight	2023-07-06	Semi-Annually	32	2.55%
DRX.L	Dividend Knight	2023-08-24	Semi-Annually	19	2.48%
SMS.L	Dividend Knight	2023-07-06	Quarterly	13	2.02%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0661	1.500	8.68	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0406	1.200	8.65	10.00	[0 - 0.3]
returnOnEquityTTM	0.0866	1.500	-0.149	-0.223	[0.1 - 1]
payoutRatioTTM	0.721	-1.000	2.79	-2.79	[0 - 1]
currentRatioTTM	1.568	0.800	7.16	5.73	[1 - 3]
quickRatioTTM	0.831	0.800	9.82	7.85	[0.8 - 2.5]
cashRatioTTM	0.153	1.500	-0.261	-0.391	[0.2 - 2]
debtRatioTTM	0.254	-1.500	5.76	-8.64	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	2.68	2.00	9.11	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.939	2.00	9.03	10.00	[0 - 20]
debtEquityRatioTTM	0.542	-1.500	7.83	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.489	1.000	5.18	5.18	[0.2 - 0.8]
operatingProfitMarginTTM	0.215	1.000	7.69	7.69	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.510	1.000	8.28	8.28	[0.2 - 2]
assetTurnoverTTM	0.614	0.800	9.24	7.39	[0.5 - 2]
Total Score				9.93

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	29.31	1.000	7.14	0	[1 - 100]
returnOnEquityTTM	0.0866	2.50	-0.0956	-0.223	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.939	2.00	9.35	10.00	[0 - 30]
dividendYielPercentageTTM	2.15	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.68	2.00	9.11	10.00	[0 - 30]
payoutRatioTTM	0.721	1.500	2.79	-2.79	[0 - 1]
pegRatioTTM	-119.14	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.211	1.000	7.21	0	[0.1 - 0.5]
Total Score				3.83

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.